ClinicalTrials.gg
CompletedNCT07193901Updated Sep 9, 2026

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior

A Phase 2 interventional study of Low Dose PRT042 nasal spray and median Dose PRT042 nasal spray in Major Depressive Disorder (MDD, sponsored by Sichuan Purity Pharmaceutical Technology Co., Ltd.. Completed at 15 sites in China. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Sichuan Purity Pharmaceutical Technology Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled May 2025, registered Sep 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 207 studies in Depressive Disorder, Major with a site in China — 75 open to participants now, 77 under way, 5 of them phase 3. Depressive Disorder, Major · China.

Enrollment
102nd of 174
98 · median 120
Started
2025
with 22 others
Phase 2
19 of 207
3 open now
Registered
168th of 207
by date

Among the 207 studies in Depressive Disorder, Major with a site in China, this one is the 102nd largest by enrollment of the 174 interventional ones that give a count, is one of 23 that started in 2025, is one of 19 in phase 2, and was the 168th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

75 of the 207 studies in Depressive Disorder, Major with a site in China are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 207 studies in Depressive Disorder, Major with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to learn about:

  • To evaluate the efficacy of PRT-042 nasal spray for the Rapid Reduction of the depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior
  • To evaluate the safety and pharmacokinetic (PK) characteristics after multiple dose of PRT-042 nasal spray in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior
03

Conditions studied

  • Major Depressive Disorder (MDD
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must meet (5th edition) (DSM-5) diagnostic criteria for Major Depressive Disorder (MDD), without psychotic features, based upon clinical assessment and confirmed by the Mini International Psychiatric Interview (MINI) .
  2. Participants must have current suicidal ideation with intent, confirmed by a "Yes" response to Question B3 [Think (even momentarily) about harming or of hurting or of injuring yourself: with at least some intent or awareness that you might die as a result; or think about suicide (ie, about killing yourself)?] and Question B10 [Intend to act on thoughts of killing yourself?] obtained from the MINI.
  3. Participant has a Montgomery Asberg Depression Rating Scale (MADRS) total score of greater than (≥) 28 and the score for item 10"suicide ideation" of greater than (≥) 3 predose on Day 1

Exclusion criteria

Exclusion Criteria:

  1. Participant has a current diagnosis of bipolar (or related disorders), antisocial personality disorder, or obsessive compulsive disorder.
  2. Participant has a current clinical diagnosis of autism, dementia, or intellectual disability.
  3. Participant has a current or prior DSM-5 diagnosis of a psychotic disorder, or MDD with psychotic features .
  4. Participant meets the DSM-5 severity criteria for moderate or severe substance or alcohol use disorder, within the 6 months before screening
  5. Participant has a current or prior diagnosis of a reatment resistant depression
  6. Any nasal conditions or diseases that, in the investigator's judgment, may significantly affect the administration or absorption of a nasal product.
  7. Participant has a history of within 5 years before screening
  8. Pregnant or breastfeeding women, or those with a positive pregnancy test result during screening.
  9. Previous participation in another clinical trial and receiving the drug within 3 months prior to dosing.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    Low Dose PRT042 nasal spray

    Drug: Low Dose PRT042 nasal spray

  • Experimental
    median Dose PRT042 nasal spray

    Drug: median Dose PRT042 nasal spray

  • Experimental
    high Dose PRT042 nasal spray

    Drug: high dose PRT042 nasal spray

  • Placebo comparator
    placebo

    Drug: placebo

Interventions

  • DrugLow Dose PRT042 nasal spray

    two times a week, for 4 weeks

  • Drugmedian Dose PRT042 nasal spray

    two times a week, for 4 weeks

  • Drughigh dose PRT042 nasal spray

    two times a week, for 4 weeks

  • Drugplacebo

    two times a week, for 4 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at 24 Hours After the First Dose (Day 2)

    The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition.

    Time frame: Baseline (Day 1, predose) and 24 hours first post dose (Day 2)

Secondary outcomes

  1. Change From Baseline in Montgomery Asberg Depression Rating Scale Total Score During Double-blind Phase

    The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition.

    Time frame: Days 1 (4 hours postdose), 4, 8, 11, 15, 18, 22 and Day 25

  2. Number of Participants who Achieved Response (≥50% decrease from baseline MADRS total score)Through the Double-blind Phase

    Time frame: Days 1 (4 hours postdose),2, 4, 8, 11, 15, 18, 22 and Day 25

  3. Number of Participants Who Achieved Remission (MADRS Total Score Less Than or Equal to [<=] 12) Through the Double-blind Phase

    Time frame: Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and Day 25

  4. 5. Change From Baseline in Clinical Global Impression- Severity of Suicidality-Revised (CGI-SS-R) During Double-blind Phase

    CGI-SS-R was derived from the Clinical Global Impression Severity Scale (CGI-S), a global rating scale that gives an overall measure of the severity of a participants illness. The CGI-SS-R rating is scored on a 7-point scale from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal participants). A higher score indicates a more severe condition and a reduction in score indicates improvement (that is, lower severity of suicidality).

    Time frame: Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and Day 25

  5. Number of Participants Who Achieved Resolution of Suicidality (CGI-SS-R Score of 0 or 1) Through Double-blind Phase

    Time frame: up to Day 25

  6. Change From Baseline in Clinical Global Impression of Imminent Suicide Risk (CGI-SR-I) Scale Total Score During Double-blind Phase

    The CGI-SR-I is a scale summarizing the clinician's best assessment of the likelihood that the participant will attempt suicide in the next 7 days. The CGI-SR-I rating is scored on a 7-point scale: where' 0 (no imminent suicide risk); 1 (minimal imminent suicide risk), 2 (mild imminent suicide risk), 3 (moderate imminent suicide risk), 4 (marked imminent suicide risk), 5 (severely imminent suicide risk), 6 (extreme imminent suicide risk). Higher score indicates a more severe condition. Negative change in score indicates improvement.

    Time frame: Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and Day 25

  7. 8. Change From Baseline in Beck Hopelessness Scale (BHS) Total Score During Double-blind Phase

    BHS is a self-reported measure to assess one's level of negative expectations or pessimism regarding future. It consists of 20 true-false items that examine respondent's attitude over past week by either endorsing a pessimistic statement or denying an optimistic statement; 9 are keyed false and 11 are keyed true. For every statement, each response was assigned score of 0 or 1. Total BHS score is sum of item responses, ranged from 0-20, where higher score represented higher level of hopelessness.

    Time frame: Baseline, Days 8 ,15 and 25

  8. Change From Baseline in Beck Scale for Suicide Ideation -Chinese Version (BSI-CV) Total Score During Double-blind Phase

    BSI-CV is a self-reported measure with 19 items, scored on a 3-point scale (0 to 2). The final score ranges from 0 to 38, with higher scores indicating a greater likelihood of suicide.

    Time frame: Baseline, Days 8 ,15 and 25

  9. Number of Participants With Treatment Emergent Adverse Events (TEAEs)、Vital Signs Abnormalities、Abnormal Electrocardiogram (ECG) Values et al: DB Treatment Phase

    Time frame: up to Day 25

  10. Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity])

    Time frame: up to Day 25

  11. Maximum Plasma Concentration [Cmax]

    Time frame: up to Day 25

  12. plasma elimination half-life [T1/2]

    Time frame: up to Day 25

07

Study locations

15 sites
  • The Sixth Hospital of Peking University
    Beijin, China
  • BEIjing AnDing hospital capital medical university
    Beijing, China
  • Beijing Huilongguan Hospital
    Beijing, China
  • Brain Hospital of Hunan Province
    Changsha, China
  • The Second Xiangya Hospital of Central South University
    Changsha, China
  • The Fourth People's Hospital of Chengdu
    Chengdu, China
  • Hangzhou Seventh People's Hospital
    Hangzhou, China
  • Hefei Fourth People's Hospital(Anhui Mental Health Prevention and Treatment Center)
    Hefei, China
  • The fourth affiliated hospital of Anhui medical university
    Hefei, China
  • The Affiliated Hospital of Southwest Medical University
    Luzhou, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, China
  • The affiliated Kangning Hospital of Ningbo University
    Ningbo, China
  • Suzhou Guangji Hospital
    Suzhou, China
  • Wuxi Mental Health Center
    Wuxi, China
  • Zhumadian Second People's Hospital(Zhumadian Psychiatric Hospital )
    Zhumadian, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Apr 2026, 10 months.

Of 99 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 10 months is below that.

Counting every sponsor, half of 198 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2025
First posted
Sep 26, 2025
StartActual
May 27, 2025
Primary completionActual
Apr 10, 2026
CompletionActual
Jun 1, 2026
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07193901
Lead sponsor
Sichuan Purity Pharmaceutical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Sep 26, 2025
Start date
May 27, 2025
Primary completion
Apr 10, 2026
Completion
Jun 1, 2026
Last update
Sep 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion